Who we are
A team of highly skilled and experienced professionals, passionate about bringing new medical technologies to the market, and fully committed to improving the way cancer patients are treated today.
2cureX was founded in 2006 in Copenhagen with the aim of improving patients’ response to treatments. Ever since, the company has been in a continuous quest for the optimal technology to predict treatment efficacy on individual patients. This quest crystallized in 2021 with the launch of the first IndiTreat® IVD test.
We are present in 20 countries across Europe, directly and through a network of distributors. We have a clinical testing lab in Copenhagen, where we also concentrate our R&D activities. Our German affiliate, 2cureX GmbH was established in 2015.
2cureX has been listed on the Nasdaq First North Growth Market under the symbol 2CUREX and ISIN SE0010468124 since 2017.